Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.23.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating Activities:    
Net loss $ (8,992) $ (7,573)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 4] 58 60
Stock-based compensation [note 8[c], note 8[e], note 8[f] and note 8[g]] 1,085 823
Shares issued as settlement with trade vendor   26
Accrued interest on SVB convertible debt [note 7] 300 271
Changes in operating assets and liabilities:    
Grant receivable [note 3] 16 153
Prepaid expenses and other assets 886 (10)
Accounts payable (597) (423)
Accrued liabilities other 296 300
Accrued clinical liabilities (366) 870
Accrued compensation (931) (1,277)
Lease obligation [note 9] (58) 1
Net cash used in operating activities (8,303) (6,779)
Financing Activities:    
Proceeds from exercise of warrants 77 24
Proceeds from ATM, net of issuance costs   91
Financing costs relating to convertible debt with SVB   (20)
Financing costs relating to November 2022 private placement (30)  
Net cash provided by financing activities 47 95
Effect of exchange rate changes on cash (1) (1)
Net decrease in cash, cash equivalents and restricted cash (8,257) (6,685)
Cash, cash equivalents and restricted cash at beginning of the period 24,821 43,072
Cash, cash equivalents and restricted cash at end of the period $ 16,564 $ 36,387